Edition:
United States

ICAD Inc (ICAD.OQ)

ICAD.OQ on NASDAQ Stock Exchange Capital Market

3.56USD
17 Nov 2017
Change (% chg)

$0.19 (+5.64%)
Prev Close
$3.37
Open
$3.40
Day's High
$3.63
Day's Low
$3.40
Volume
6,306
Avg. Vol
7,627
52-wk High
$6.01
52-wk Low
$3.12

Chart for

About

iCAD, Inc. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments:... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $58.37
Shares Outstanding(Mil.): 16.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 15.84 15.79
EPS (TTM): -- -- --
ROI: -- 7.74 12.01
ROE: -- 11.11 15.91

BRIEF-ICAD reports Q3 GAAP loss per share $0.42

* Q3 revenue rose 17 percent to $7.0 million Source text for Eikon: Further company coverage:

Nov 08 2017

BRIEF-ICAD Inc ‍announces approval of Xoft Axxent balloon applicators by China FDA

* ICAD Inc - ‍announces approval of Xoft Axxent balloon applicators by China Food & Drug Administration for treatment of early-stage breast cancer​ Source text for Eikon: Further company coverage:

Aug 30 2017

BRIEF-ICAD reports Q2 loss per share $0.16

* iCAD reports second quarter 2017 financial results and announces $13 million credit facility with silicon valley bank

Aug 08 2017

BRIEF-iCAD provides positive eBx system data in skin cancer patients

* Icad announces positive study results comparing use of company’s xoft® axxent® electronic brachytherapy (ebx®) system® to mohs surgery in treatment of early-stage non-melanoma skin cancer Source text for Eikon: Further company coverage:

Jul 19 2017

Earnings vs. Estimates